-
Development Pipeline
Development-stage programs in gout and cancer -
Gout
First and next-generation URAT1 transporter inhibitors for the treatment of hyperuricemia and gout -
Cancer
BAY 86-9766 (formerly known as RDEA119), a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer, is being developed under a global license agreement with Bayer Healthcare AG
On June 19, 2012, AstraZeneca PLC completed its acquisition of Ardea Biosciences, Inc. Upon completion of the merger, Ardea became a wholly owned subsidiary of AstraZeneca. The total transaction value was approximately $1.26 billion. See Ardea's public filings with the Securities and Exchange Commission for more information.